Literature DB >> 6681870

Effects of 3-OM-dopa on monoamine metabolism in rat brain.

J J Gervas, V Muradás, E Bazán, E G Aguado, J G de Yébenes.   

Abstract

We studied the effects of 3-methoxy, 4-hydroxy-phenylalanine (3-OM-dopa) on monoamine turnover, L-3-4-dihydroxy-phenylalanine (L-dopa) reversal of catecholamine depletion induced by alpha-methyl-paratyrosine (alpha-MT), and the passage of L-dopa across the blood-brain barrier of the rat brain. 3-OM-dopa did not affect monoamine turnover but interfered with restoration of dopamine levels by L-dopa. In addition, systemic 3-OM-dopa decreased brain uptake of 14C-L-dopa. High 3-OM-dopa blood levels may interfere with the therapeutic response to L-dopa in parkinsonism.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6681870     DOI： 10.1212/wnl.33.3.278

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  21 in total

1.  Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors:  M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

3.  Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.

Authors:  H Baas; F Zehrden; R Selzer; R Kohnen; J Loetsch; S Harder
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.

Authors:  A P Kent; G M Stern; R A Webster
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

5.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.

Authors:  J G Nutt; W R Woodward; J H Carter; T L Trotman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

7.  The role of 3-O-methyldopa in the side effects of L-dopa.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

8.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Authors:  Luis Almeida; José Francisco Rocha; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

10.  Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

Authors:  José Francisco Rocha; Luis Almeida; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.